LUGANO, Switzerland, September 5 /PRNewswire/ -- The 33rd ESMO Congress in Stockholm, the premier European congress in Oncology, serves as a meeting place for medical oncologists, as well as a focal point to exchange ideas with colleagues from other disciplines.
The Congress Centre will be the venue for interdisciplinary
interaction, a teaching ground, and a place to discuss critical issues for
European oncology such as cancer research in Europe, the training of young
oncologists and better integration of medical oncology with other
specialties and patient advocacy groups.
Highlights of Congress Program:
Please respect individual embargo dates/times
Access to drugs
European disparities in access to cancer drugs
(Embargoed until Monday, 15 September 2008, 12:30 CEST)
New research has highlighted stark disparities in access to the latest
cancer drugs across European Union nations. Dr. Nils Wilking from the
Karolinska Institute in Stockholm gathered data on the sales of newer drugs
per inhabitant of each country provided by pharmaceutical industry
consultants IMS Health. His group's focus was on the uptake of newer
'targeted' drugs over the past 10 years in 27 countries.
Significant benefits in non-small-cell lung cancer from customising
(Embargoed until Saturday 13 September 2008, 12:45 CEST)
Lung cancer patients whose tumours carry specific genetic mutations can
achieve significantly longer survival when treated with targeted therapies
such as erlotinib, Spanish researchers report. Investigators from the
Spanish Lung Cancer Group conducted the largest-ever study to examine the
benefits of customising lung cancer treatment based on mutations in the
epidermal growth factor receptor (EGFR) gene.
Phase II trial of pazopanib before surgery in early lung cancer
(Embargoed until Monday, 15 September 2008, 10:45 CEST)
|SOURCE ESMO European Society for Medical Oncology|
Copyright©2008 PR Newswire.
All rights reserved